Concepts (154)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Glioma | 7 | 2023 | 3349 | 1.250 |
Why?
|
| Brain Neoplasms | 12 | 2023 | 8784 | 1.110 |
Why?
|
| Indigofera | 1 | 2023 | 2 | 0.940 |
Why?
|
| Radiosurgery | 3 | 2021 | 1299 | 0.780 |
Why?
|
| Spinal Neoplasms | 2 | 2018 | 697 | 0.770 |
Why?
|
| Nucleotides | 1 | 2023 | 449 | 0.730 |
Why?
|
| Lymphopenia | 1 | 2022 | 275 | 0.730 |
Why?
|
| Malignant Carcinoid Syndrome | 1 | 2017 | 30 | 0.590 |
Why?
|
| Neurosciences | 1 | 2022 | 347 | 0.580 |
Why?
|
| Neoplasms | 7 | 2023 | 21375 | 0.560 |
Why?
|
| Palliative Care | 3 | 2020 | 3465 | 0.500 |
Why?
|
| Research Report | 1 | 2018 | 345 | 0.490 |
Why?
|
| Phenylacetates | 1 | 2014 | 114 | 0.470 |
Why?
|
| Leukemia | 1 | 2022 | 1476 | 0.470 |
Why?
|
| Radiation Injuries | 1 | 2020 | 1167 | 0.420 |
Why?
|
| Receptors, GABA | 1 | 2014 | 300 | 0.400 |
Why?
|
| Radiation Oncology | 1 | 2018 | 548 | 0.400 |
Why?
|
| Rectal Neoplasms | 1 | 2020 | 1157 | 0.390 |
Why?
|
| Isocitrate Dehydrogenase | 4 | 2023 | 865 | 0.390 |
Why?
|
| Spinal Fractures | 1 | 2018 | 682 | 0.390 |
Why?
|
| Pain Measurement | 1 | 2020 | 3426 | 0.370 |
Why?
|
| Joint Instability | 1 | 2018 | 792 | 0.360 |
Why?
|
| Neurotransmitter Agents | 1 | 2014 | 648 | 0.350 |
Why?
|
| Photons | 1 | 2014 | 584 | 0.350 |
Why?
|
| Neoadjuvant Therapy | 1 | 2020 | 2733 | 0.340 |
Why?
|
| Combined Modality Therapy | 2 | 2020 | 8475 | 0.330 |
Why?
|
| gamma-Aminobutyric Acid | 1 | 2014 | 1114 | 0.300 |
Why?
|
| Glioblastoma | 1 | 2022 | 3434 | 0.290 |
Why?
|
| Periodicals as Topic | 1 | 2018 | 1413 | 0.290 |
Why?
|
| Medical Oncology | 1 | 2018 | 2227 | 0.270 |
Why?
|
| Mortality | 1 | 2017 | 2812 | 0.270 |
Why?
|
| Patient Selection | 1 | 2018 | 4106 | 0.270 |
Why?
|
| Pain | 1 | 2020 | 4950 | 0.260 |
Why?
|
| Karnofsky Performance Status | 3 | 2020 | 166 | 0.250 |
Why?
|
| Salicylanilides | 1 | 2022 | 15 | 0.220 |
Why?
|
| Radiotherapy Dosage | 2 | 2021 | 2854 | 0.210 |
Why?
|
| Anxiety | 1 | 2017 | 4275 | 0.210 |
Why?
|
| Melanoma | 1 | 2020 | 5526 | 0.200 |
Why?
|
| Nervous System Physiological Phenomena | 1 | 2022 | 116 | 0.190 |
Why?
|
| Dacarbazine | 1 | 2022 | 560 | 0.170 |
Why?
|
| Transaminases | 1 | 2018 | 192 | 0.150 |
Why?
|
| Depression | 1 | 2017 | 7672 | 0.150 |
Why?
|
| Hydroxyindoleacetic Acid | 1 | 2017 | 93 | 0.150 |
Why?
|
| Histone Code | 1 | 2018 | 156 | 0.140 |
Why?
|
| Flushing | 1 | 2017 | 51 | 0.140 |
Why?
|
| Jumonji Domain-Containing Histone Demethylases | 1 | 2018 | 172 | 0.140 |
Why?
|
| Triazoles | 1 | 2022 | 896 | 0.140 |
Why?
|
| Workflow | 1 | 2021 | 813 | 0.140 |
Why?
|
| Humans | 23 | 2023 | 735458 | 0.130 |
Why?
|
| Necrosis | 1 | 2020 | 1598 | 0.130 |
Why?
|
| Carcinoid Tumor | 1 | 2017 | 231 | 0.130 |
Why?
|
| Indoles | 1 | 2023 | 1811 | 0.130 |
Why?
|
| Digestive System Surgical Procedures | 1 | 2020 | 566 | 0.130 |
Why?
|
| Radiotherapy, Adjuvant | 1 | 2020 | 1750 | 0.130 |
Why?
|
| Retinoblastoma Protein | 1 | 2018 | 676 | 0.120 |
Why?
|
| Photochemical Processes | 1 | 2014 | 82 | 0.120 |
Why?
|
| Drug Stability | 1 | 2014 | 291 | 0.110 |
Why?
|
| Mutation | 5 | 2023 | 29406 | 0.110 |
Why?
|
| Carcinoma, Renal Cell | 2 | 2018 | 3145 | 0.110 |
Why?
|
| Glutamic Acid | 1 | 2018 | 1150 | 0.110 |
Why?
|
| DNA Damage | 1 | 2022 | 2368 | 0.110 |
Why?
|
| Chemotherapy, Adjuvant | 1 | 2020 | 3444 | 0.100 |
Why?
|
| Radiotherapy Planning, Computer-Assisted | 1 | 2021 | 1640 | 0.100 |
Why?
|
| Enzyme Inhibitors | 1 | 2022 | 3686 | 0.100 |
Why?
|
| Kidney Neoplasms | 2 | 2018 | 4256 | 0.100 |
Why?
|
| Patch-Clamp Techniques | 1 | 2014 | 931 | 0.100 |
Why?
|
| Qualitative Research | 1 | 2020 | 2726 | 0.100 |
Why?
|
| Aged, 80 and over | 7 | 2020 | 56770 | 0.100 |
Why?
|
| Gastrointestinal Neoplasms | 1 | 2019 | 973 | 0.100 |
Why?
|
| Salvage Therapy | 1 | 2017 | 1260 | 0.090 |
Why?
|
| Spine | 1 | 2018 | 1101 | 0.090 |
Why?
|
| Radiotherapy | 1 | 2017 | 1503 | 0.090 |
Why?
|
| Pyrimidines | 1 | 2022 | 2973 | 0.090 |
Why?
|
| Diarrhea | 1 | 2017 | 1313 | 0.090 |
Why?
|
| Female | 12 | 2022 | 376708 | 0.090 |
Why?
|
| Adult | 9 | 2023 | 212371 | 0.090 |
Why?
|
| Middle Aged | 10 | 2020 | 211305 | 0.090 |
Why?
|
| Pituitary Neoplasms | 1 | 2018 | 1295 | 0.090 |
Why?
|
| Molecular Structure | 1 | 2014 | 1871 | 0.080 |
Why?
|
| Tumor Microenvironment | 1 | 2022 | 3644 | 0.080 |
Why?
|
| DNA | 1 | 2023 | 7185 | 0.080 |
Why?
|
| Interneurons | 1 | 2014 | 579 | 0.080 |
Why?
|
| Survival Analysis | 2 | 2020 | 10060 | 0.080 |
Why?
|
| Evoked Potentials | 1 | 2014 | 1012 | 0.080 |
Why?
|
| Risk Assessment | 2 | 2020 | 22901 | 0.080 |
Why?
|
| Orthopedic Procedures | 1 | 2018 | 1264 | 0.080 |
Why?
|
| Synaptic Transmission | 1 | 2014 | 1161 | 0.070 |
Why?
|
| Aged | 8 | 2020 | 161495 | 0.070 |
Why?
|
| Male | 10 | 2020 | 346169 | 0.070 |
Why?
|
| Drug Resistance, Neoplasm | 1 | 2022 | 5135 | 0.070 |
Why?
|
| Retrospective Studies | 7 | 2020 | 76887 | 0.070 |
Why?
|
| Neurosurgical Procedures | 1 | 2017 | 1934 | 0.070 |
Why?
|
| Cerebellum | 1 | 2014 | 1467 | 0.070 |
Why?
|
| Molecular Targeted Therapy | 1 | 2018 | 2729 | 0.070 |
Why?
|
| Clinical Trials as Topic | 1 | 2022 | 7764 | 0.070 |
Why?
|
| Neoplasm Proteins | 1 | 2018 | 3627 | 0.070 |
Why?
|
| Biomedical Research | 1 | 2021 | 3270 | 0.060 |
Why?
|
| Thyroid Neoplasms | 1 | 2018 | 2257 | 0.060 |
Why?
|
| Consensus | 1 | 2023 | 2975 | 0.060 |
Why?
|
| Breast Neoplasms | 2 | 2020 | 20517 | 0.050 |
Why?
|
| Prognosis | 5 | 2020 | 28548 | 0.050 |
Why?
|
| DNA-Binding Proteins | 1 | 2018 | 9472 | 0.050 |
Why?
|
| Mice | 3 | 2022 | 79548 | 0.050 |
Why?
|
| Animals | 4 | 2022 | 165479 | 0.040 |
Why?
|
| Young Adult | 4 | 2018 | 56151 | 0.040 |
Why?
|
| Genes, Retinoblastoma | 1 | 2018 | 126 | 0.040 |
Why?
|
| Minor Histocompatibility Antigens | 1 | 2018 | 291 | 0.040 |
Why?
|
| Pregnancy Proteins | 1 | 2018 | 223 | 0.040 |
Why?
|
| Heart Septal Defects | 1 | 2018 | 185 | 0.040 |
Why?
|
| Glutarates | 1 | 2018 | 230 | 0.040 |
Why?
|
| Treatment Outcome | 2 | 2020 | 62430 | 0.040 |
Why?
|
| Lung Neoplasms | 1 | 2020 | 13033 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 52611 | 0.030 |
Why?
|
| Multivariate Analysis | 2 | 2020 | 11939 | 0.030 |
Why?
|
| Receptors, Progesterone | 1 | 2020 | 1096 | 0.030 |
Why?
|
| Integrases | 1 | 2018 | 510 | 0.030 |
Why?
|
| Cranial Irradiation | 1 | 2018 | 390 | 0.030 |
Why?
|
| Genetic Engineering | 1 | 2021 | 932 | 0.030 |
Why?
|
| Proportional Hazards Models | 2 | 2020 | 12113 | 0.030 |
Why?
|
| Transgenes | 1 | 2018 | 1002 | 0.030 |
Why?
|
| Risk Factors | 1 | 2020 | 70952 | 0.030 |
Why?
|
| Magnetic Resonance Imaging | 1 | 2021 | 35374 | 0.030 |
Why?
|
| Estrogens | 1 | 2020 | 1517 | 0.030 |
Why?
|
| Tamoxifen | 1 | 2018 | 954 | 0.030 |
Why?
|
| BRCA1 Protein | 1 | 2020 | 1110 | 0.030 |
Why?
|
| Xenograft Model Antitumor Assays | 1 | 2021 | 3489 | 0.030 |
Why?
|
| Oxidation-Reduction | 1 | 2018 | 2170 | 0.030 |
Why?
|
| Hemoglobins | 1 | 2018 | 1505 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2018 | 3606 | 0.030 |
Why?
|
| Propensity Score | 1 | 2017 | 1792 | 0.020 |
Why?
|
| Receptor, erbB-2 | 1 | 2020 | 2447 | 0.020 |
Why?
|
| Recombinant Fusion Proteins | 1 | 2018 | 3712 | 0.020 |
Why?
|
| Kaplan-Meier Estimate | 1 | 2019 | 6365 | 0.020 |
Why?
|
| Angiogenesis Inhibitors | 1 | 2018 | 2010 | 0.020 |
Why?
|
| Referral and Consultation | 1 | 2020 | 3475 | 0.020 |
Why?
|
| Cause of Death | 1 | 2018 | 3517 | 0.020 |
Why?
|
| Fibroblasts | 1 | 2018 | 4036 | 0.020 |
Why?
|
| Homeostasis | 1 | 2018 | 3256 | 0.020 |
Why?
|
| Alleles | 1 | 2018 | 6795 | 0.020 |
Why?
|
| Follow-Up Studies | 2 | 2018 | 38356 | 0.020 |
Why?
|
| Adolescent | 3 | 2018 | 85125 | 0.020 |
Why?
|
| Echocardiography | 1 | 2018 | 4772 | 0.020 |
Why?
|
| Survival Rate | 1 | 2018 | 12513 | 0.020 |
Why?
|
| Cytokines | 1 | 2018 | 7175 | 0.010 |
Why?
|
| Immunotherapy | 1 | 2018 | 4463 | 0.010 |
Why?
|
| Disease Models, Animal | 1 | 2021 | 17700 | 0.010 |
Why?
|
| Cell Line, Tumor | 1 | 2018 | 16463 | 0.010 |
Why?
|
| Disease Progression | 1 | 2017 | 13117 | 0.010 |
Why?
|
| Mice, Inbred C57BL | 1 | 2018 | 21329 | 0.010 |
Why?
|
| Quality of Life | 1 | 2020 | 12733 | 0.010 |
Why?
|
| Neoplasm Recurrence, Local | 1 | 2017 | 9141 | 0.010 |
Why?
|
| Cohort Studies | 1 | 2019 | 39931 | 0.010 |
Why?
|
| Time Factors | 1 | 2017 | 39212 | 0.010 |
Why?
|
| Antineoplastic Agents | 1 | 2018 | 13478 | 0.010 |
Why?
|
Concepts
(154)
Derived automatically from this person's publications.
Explore
_
Co-Authors
(68)
People in Profiles who have published with this person.
Explore
_
Similar People
(60)
People who share similar concepts with this person.
Explore
_
Same Department
People in same department with this person.
Explore
_